The risk of cancer among insulin glargine users in Lithuania: A retrospective population-based study.

IF 1.7 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Open Medicine Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI:10.1515/med-2024-1017
Justinas Jonusas, Mingailė Drevinskaitė, Donata Linkeviciute-Ulinskiene, Adomas Ladukas, Aušvydas Patašius, Lina Zabulienė, Giedrė Smailytė
{"title":"The risk of cancer among insulin glargine users in Lithuania: A retrospective population-based study.","authors":"Justinas Jonusas, Mingailė Drevinskaitė, Donata Linkeviciute-Ulinskiene, Adomas Ladukas, Aušvydas Patašius, Lina Zabulienė, Giedrė Smailytė","doi":"10.1515/med-2024-1017","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to determine the association between insulin glargine usage and the potential increase in cancer risk among the Lithuanian population diagnosed with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>A retrospective cohort study was conducted. The cohort of insulin users was established by identifying all male and female patients diagnosed with T2DM, as recorded in the National Health Insurance Fund database between 1 January 2000 and 31 December 2012. The risk of cancer among insulin glargine users was compared with the risk in non-glargine insulin users. Cox proportional hazard models were used to estimate hazard ratios (HR) and their 95% confidence intervals (CI).</p><p><strong>Results: </strong>The overall cancer risk for all sites combined showed no significant difference (HR 0.84, 95% CI 0.67-1.05). Although a general decrease in the risk of cancers was observed at most sites for glargine users, the use of insulin glargine was associated with a non-significant increase in the risk of mouth and pharynx, stomach, non-melanoma skin, breast, cervical, ovarian, and central nervous system cancers. There was a tendency for a lower risk of colon, rectum, rectosigmoid, and anus cancer among glargine users (HR 0.45, 95% CI 0.18-1.12, <i>p</i> = 0.09).</p><p><strong>Conclusions: </strong>Our research contributes to the growing body of evidence showing that insulin glargine is not associated with an increased risk of all cancers or specific types of cancer.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"19 1","pages":"20241017"},"PeriodicalIF":1.7000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491771/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2024-1017","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: The aim of this study was to determine the association between insulin glargine usage and the potential increase in cancer risk among the Lithuanian population diagnosed with type 2 diabetes mellitus (T2DM).

Methods: A retrospective cohort study was conducted. The cohort of insulin users was established by identifying all male and female patients diagnosed with T2DM, as recorded in the National Health Insurance Fund database between 1 January 2000 and 31 December 2012. The risk of cancer among insulin glargine users was compared with the risk in non-glargine insulin users. Cox proportional hazard models were used to estimate hazard ratios (HR) and their 95% confidence intervals (CI).

Results: The overall cancer risk for all sites combined showed no significant difference (HR 0.84, 95% CI 0.67-1.05). Although a general decrease in the risk of cancers was observed at most sites for glargine users, the use of insulin glargine was associated with a non-significant increase in the risk of mouth and pharynx, stomach, non-melanoma skin, breast, cervical, ovarian, and central nervous system cancers. There was a tendency for a lower risk of colon, rectum, rectosigmoid, and anus cancer among glargine users (HR 0.45, 95% CI 0.18-1.12, p = 0.09).

Conclusions: Our research contributes to the growing body of evidence showing that insulin glargine is not associated with an increased risk of all cancers or specific types of cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
立陶宛格列卫胰岛素使用者的癌症风险:一项基于人口的回顾性研究。
研究目的本研究旨在确定立陶宛确诊的 2 型糖尿病(T2DM)患者使用格列卫胰岛素与癌症风险潜在增加之间的关联:方法:进行了一项回顾性队列研究。胰岛素使用者队列的建立是通过识别2000年1月1日至2012年12月31日期间国家健康保险基金数据库中记录的所有确诊为T2DM的男性和女性患者。研究人员将使用格列美脲胰岛素的患者罹患癌症的风险与未使用格列美脲胰岛素的患者罹患癌症的风险进行了比较。采用考克斯比例危险模型估算危险比(HR)及其95%置信区间(CI):结果:所有部位的总体癌症风险没有明显差异(HR 0.84,95% CI 0.67-1.05)。虽然格列卫使用者患癌症的风险在大多数部位普遍降低,但使用格列卫胰岛素与口腔和咽部、胃、非黑素瘤皮肤癌、乳腺癌、宫颈癌、卵巢癌和中枢神经系统癌症风险的增加无明显关联。格列卫使用者患结肠癌、直肠癌、直肠乙状结肠癌和肛门癌的风险有降低的趋势(HR 0.45,95% CI 0.18-1.12,P = 0.09):越来越多的证据表明,格列卫胰岛素不会增加罹患所有癌症或特定类型癌症的风险,我们的研究为这些证据做出了贡献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Open Medicine
Open Medicine Medicine-General Medicine
CiteScore
3.00
自引率
0.00%
发文量
153
审稿时长
20 weeks
期刊介绍: Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The primary goal of the journal has always been a focus on maintaining the high quality of its published content. Its mission is to facilitate the exchange of ideas between medical science researchers from different countries. Papers connected to all fields of medicine and public health are welcomed. Open Medicine accepts submissions of research articles, reviews, case reports, letters to editor and book reviews.
期刊最新文献
Detection of serum FOXM1 and IGF2 in patients with ARDS and their correlation with disease and prognosis. Fluoxetine inhibited RANKL-induced osteoclastic differentiation in vitro. The potential risk factors of postoperative cognitive dysfunction for endovascular therapy in acute ischemic stroke with general anesthesia. Carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel treatment for LACC: A randomized, open-label, phase II clinical study. Iron in ventricular remodeling and aneurysms post-myocardial infarction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1